NuCana Compliant with All Nasdaq Continued Listing Criteria
1. NuCana is compliant with Nasdaq listing requirements as of September 4, 2025. 2. The company anticipates funding operations into 2029 from existing cash reserves. 3. NCNA plans to deliver key data readouts on cancer therapies in upcoming years. 4. Management emphasizes addressing limitations in current cancer treatment methodologies.